Savara Announces Participation in the Leerink Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday,
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need.
Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...
Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...
Hosted on MSN13d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Leerink downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a $2 price target Discover the Best Stocks and Maximize ...
Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback